Template:Oral hypoglycemics and insulin analogs: Difference between revisions
Content deleted Content added
Phase 2 for T2 diabetes alone ( https://beta.clinicaltrials.gov/search?cond=Diabetes%20Mellitus%20Type%202&term=LY3437943 ), while phase 3 for weight loss (for people with or without diabetes T2) |
Mazdutide for diabetes as well: https://diabetesjournals.org/care/article/doi/10.2337/dc23-1287/153858/Efficacy-and-Safety-of-Mazdutide-in-Chinese |
||
| Line 122: | Line 122: | ||
*[[Taspoglutide]]<sup>†</sup> |
*[[Taspoglutide]]<sup>†</sup> |
||
{{navbox|child| |
{{navbox|child| |
||
group1=[[GLP1 poly-agonist peptides |
group1=[[GLP1 poly-agonist peptides]] |
||
|list1= |
|list1= |
||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
{{navbox|child| |
|||
| ⚫ | |||
| ⚫ | |||
|list1= |
|||
| ⚫ | |||
}} |
|||
}} |
}} |
||
| group3 = [[Dipeptidyl peptidase-4 inhibitor|DPP-4 inhibitor]]s/"gliptins" |
| group3 = [[Dipeptidyl peptidase-4 inhibitor|DPP-4 inhibitor]]s/"gliptins" |
||
| list3 = |
| list3 = |
||
Revision as of 19:54, 3 December 2023
This template's initial visibility currently defaults to autocollapse, meaning that if there is another collapsible item on the page (a navbox, sidebar, or table with the collapsible attribute), it is hidden apart from its title bar; if not, it is fully visible.
To change this template's initial visibility, the |state= parameter may be used:
{{Oral hypoglycemics and insulin analogs|state=collapsed}}will show the template collapsed, i.e. hidden apart from its title bar.{{Oral hypoglycemics and insulin analogs|state=expanded}}will show the template expanded, i.e. fully visible.